Background
==========

The incidence of inflammatory bowel disease (IBD) is increasing worldwide including Denmark.[@b1-clep-8-607]--[@b4-clep-8-607] During the last decades, introduction of biological therapy has changed the management of ulcerative colitis (UC) and Crohn's disease (CD).[@b5-clep-8-607] As a consequence, the medication-related expenses of IBD therapy have increased substantially.[@b6-clep-8-607] International and national treatment guidelines support clinicians in treatment decisions and rational clinical use of biological therapy and are used by health care providers to prioritize and regulate the costs of therapy.

Aim of The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease
========================================================================================

To ensure a rational use of biological drugs and adherence to national guidelines, The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease (BIO-IBD) has been established in 2015. First, the aim of the database is to ensure that the choice of biological therapy and the clinical management of patients with IBD receiving biological treatment are in accordance with the national clinical guidelines[@b7-clep-8-607] and second, the database can be used for register-based clinical epidemiological research.

The database is planned to start in March 2016, and patients will be enrolled consecutively when biological treatment is initiated. Based on recent data from The Danish National Patient Registry (NPR), we estimate that 1,200--1,300 new biological therapies are initiated each year and at a given point in time 2,700--2,800 patients are treated with biological agents.

Study population
================

In Denmark (population of \~5.5 million people), all citizens have free access to a tax-supported health care system, and biological therapy is only administered in public hospitals without cost to the patient.[@b8-clep-8-607]

For all Danish hospitals, both public and private, it is mandatory by Danish law to report diagnosis and clinical procedures to NPR. The completeness of coding in NPR is very high as 99% of all hospital discharges and out-patient clinics from somatic hospitals are recorded.[@b9-clep-8-607] Likewise the completeness of diagnoses of IBD in NPR is very good. In one study, the validity of the IBD diagnoses in NPR was examined using the pathology system as a reference standard, confirming that 94% of the UC and CD diagnoses were included in the NPR. The overall validity of diagnoses of CD in the NPR was 97%, and for UC 90%.[@b10-clep-8-607] Identification of patients is based on the Danish Civil Registration System (CRS). The CRS has registered all persons alive and living in Denmark since 1968, and has a very high accuracy of Danish citizens and migrations.[@b11-clep-8-607],[@b12-clep-8-607]

The availability of these nationwide Danish registries makes it possible to retrieve data on almost all patients with IBD and treatment with biological agents. Hence, the study population comprises all Danish patients with IBD (both children and adults) with UC, CD, and IBD-unclassified (IBD-U) who receive biological therapy. Patients will be enrolled consecutively when biological treatment is initiated. Eligible patients with IBD are bio-naive patients (patients never treated with biological therapy); patients previously treated with biological therapy and stopped for \>3 months, and patients already on biological therapy who, due to side effects or lack of effect, switch to another biological drug.

It is mandatory for the departments prescribing biological therapy to report these data to the BIO-IBD registry.

Quality indicators
==================

Eleven quality indicators have been defined ([Table 1](#t1-clep-8-607){ref-type="table"}). Choice, background, and level of evidence for the indicators are described in The BIO-IBD Documentarist Report.[@b13-clep-8-607] Indicators related to outcome represent clinically relevant measures, with indicator standards determined from existing literature. Indicators related to process are addressing guideline adherence and administrative issues, with indicator standards determined from consensus in the working group.

In the future, new quality indicators are to be defined and added to the registry.

Main variables
==============

The variables in the database are obtained by two methods: Data from NPR are used for registration of the IBD patient and basic information on diagnosis, use of biologic agent, and IBD-related procedures. This is supplemented with clinical information reported by the clinician using a national web-based input module (Supplementary materials 1, 2, and 3). This is believed to ensure the best possible data quality. Data harvested from NPR: diagnosis, previous biological therapy, surgery, endoscopic procedures, radiology, treatment dates regarding current biological therapy, and current biological agent ([Table 2](#t2-clep-8-607){ref-type="table"}).Data reported by the clinician include: background information (diagnosis, time of diagnosis, disease manifestation, indication for biological therapy, and previous nonbiological therapy) and contact data at outpatient visit (date of the visit, relevant clinical indices \[see later\], physician's global assessment, pregnancy/breastfeeding \[women\], height \[children\], weight, dosage \[current biological agent\], nonbiological therapy, adverse events with regard to the biological agent, and treatment decision on continuing, changing, or stopping the biological agent).The clinical indices used in the database are: Harvey--Bradshaw Index for CD[@b14-clep-8-607]Abbreviated Pediatric Crohn's Disease Activity Index for children with CD[@b15-clep-8-607]Simple Clinical Colitis Activity Index for UC and IBD-U[@b16-clep-8-607]Pediatric Ulcerative Colitis Activity Index for children with UC and IBD-U[@b17-clep-8-607]Short Health Scale.[@b18-clep-8-607],[@b19-clep-8-607]

A complete list of the variables can be found in Supplementary material 2.

Data recording
==============

The clinician is required to ensure that every eligible patient is entered into the database upon start of biological therapy. It is recommended that data are entered in the database every time biological treatment is administered, but as a minimum twice yearly and every time changes in therapy, or side-effects occur or if therapy is stopped. In addition to this, there is a continuous data collection from the NPR, which will ensure that all eligible patients are registered, should the clinician fail to include the patient at the first visit. To ensure the completeness of the database, the departments involved in administering biological treatment will receive lists of patients with records of biological treatment codes from the NPR.

The quality of data in the database relies entirely on the clinician/IBD nurse and is the responsibility of the department giving biological treatment. It will only be possible to calculate the quality indicators if sufficient data is reported in the database. If it is not possible to calculate the indicators, the departments with incomplete data will be mentioned in the annual report. There is no official quality control but as the results are a public document and reported on a quarterly basis to the departments to regularly review their clinical performance, it is believed to motivate the clinicians to high quality in both treatment and reporting.

Examples of research
====================

The database will be available for research during 2016. Data will be made available by The Danish Clinical Registries (RKKP; [www.rkkp.dk](http://www.rkkp.dk)).

Administrative issues and funding
=================================

The database is administered by a steering committee, which comprises: Five members of the Danish Society of Gastroenterology and Hepatology (one member from each of the five regions in Denmark)A pediatric gastroenterologist, member of the Danish Pediatric SocietyA documentarist (clinician to compose a report on the background and evidence for the indicators)A RKKP-team (Danish Clinical Quality Databases represented by the Centre of Competence for Nationwide Clinical Registries) assigning a contact person, a data manager, an epidemiologist, and a statistician.

The members are appointed for a period of 4 years by the board of the respective societies. There is an option for one re-election.

The steering committee has no financial means of its own, but the Danish Regions' funding for clinical quality registries has secured a grant for the establishment of the database.

The BIO-IBD database operates under the Danish law on data protection, with license granted by the Danish Data Protection Agency and the Danish National Board of Health. Further individual patient consent or Ethical Review Board approval is not required according to Danish law when data are used to monitor, secure, and improve clinical quality.

Conclusion
==========

Based on the indicators defined, an annual report will state the quality of biological therapy in patients with IBD treated in Denmark, both at a national and department level together with a complete overview of the data available.

In addition, results are reported on a quarterly basis to the departments to regularly review their clinical performance. The indicators will be reported as department-specific proportions with 95% confidence intervals, and the national average will be provided for comparison. For each indicator, a standard has been developed based on the available evidence.
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![Patient flow in the database.\
**Notes:** Patients will be included at start or switch of biological therapy. A form for basic patient information, start of biological therapy, outpatient visit where biological therapy will be administered, switch of therapy, and discontinuation of biological therapy will be available at relevant time-point in course of therapy.](clep-8-607Fig1){#f1-clep-8-607}

###### 

Quality indicators

  Quality indicator                                                                                                                                                                                                 Indicator standard (%)   Type of indicator
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------------
  1CD: Percentage of patients with luminal CD for whom the indication for biological therapy is in accordance with the national guidelines                                                                          ≥80                      Process
  2CD: Percentage of CD patients with no prior biological therapy for whom the selected first-line biological therapy is in accordance with the national guidelines                                                 ≥80                      Process
  3CD: Percentage of patients with CD in maintenance therapy with a biological agent, who have a minimum of two outpatient visits per year                                                                          ≥80                      Process
  4CD: Percentage of patients in maintenance therapy with a biological agent, diagnosed with luminal CD, never having undergone surgery for CD, who have well-controlled disease (HBI score \<5 or abrPCDAI \<10)   ≥60                      Outcome
  5UC: Percentage of patients with UC for whom the indication for biological therapy is in accordance with the national guidelines                                                                                  ≥80                      Process
  6UC: Percentage of UC patients with no prior biological therapy and chronic active disease for whom the selected first-line biological therapy is in accordance with the national guidelines                      ≥80                      Process
  7IBD: Percentage of UC patients with acute severe ulcerative colitis for whom the selected first-line biological therapy is in accordance with the national guidelines                                            ≥80                      Process
  8UC: Percentage of patients with UC in maintenance therapy with a biological agent, who have a minimum of two outpatient visits per year                                                                          ≥80                      Process
  9UC: Percentage of patients with UC in maintenance therapy with a biological agent, who have well-controlled disease (SCCAI \<5 or PUCAI \<10)                                                                    ≥60                      Outcome
  10IBD: Percentage of patients with UC or CD, who are in steroid free remission after at least 6 months of biological therapy                                                                                      ≥40                      Outcome
  11IBD: Percentage of children with UC or CD in maintenance therapy with a biological agent, for whom data on height and weight is recorded in minimum two outpatient visits per year                              ≥60                      Process

**Abbreviations:** abrPCDAI, Abbreviated Pediatric Crohn's Disease Activity Index; CD, Crohn's disease; HBI, Harvey--Bradshaw Index; IBD, inflammatory bowel disease; PUCAI, Pediatric Ulcerative Colitis Index; SCCAI, Simple Clinical Colitis Activity Index; UC, ulcerative colitis.

###### 

Codes from The Danish National Patient Registry to be included in the Danish Registry for Biological Therapy: ICD-10 diagnostic codes used to identify patients with IBD

  ----------------------- -------------------------------------------------------------------------- ----------------------------------
  Crohn's disease         K50.0--50.9                                                                
  Ulcerative colitis      K51.0--51.9                                                                
  IBD unclassified        K51.9, K52.9                                                               
  Specific drug coding:                                                                              ATC-coding used with procedures:
  BOHJ18A1                Infliximab                                                                 L04AA12 or L04AB02
  BOHJ18A3                Adalimumab                                                                 L04AA17 or L04AB04
  BOHJ18A4                Golimumab                                                                  L04AB06
  BOHJ18A5                Certolizumab pegol                                                         L04AB05
  BOHJ26                  Natalizumab                                                                L04AA23
  BOHJ19H4                Vedolizumab                                                                L04AA33
  **Operation codes**                                                                                
  KJFB00                  Small bowel resection                                                      
  KJFB01                  Laparoscopic small bowel resection                                         
  KJFB20                  Ileocecal resection                                                        
  KJFB21                  Laparoscopic ileocecal resection                                           
  KJFB30                  Right side hemicolectomy                                                   
  KJFB31                  Laparoscopic right side hemicolectomy                                      
  KJFB33                  Other resection of small bowel or colon                                    
  KJFB34                  Other laparoscopic resection of small bowel or colon                       
  KJFB40                  Resection of transverse colon                                              
  KJFB41                  Laparoscopic resection of transverse colon                                 
  KJFB43                  Left side hemicolectomy                                                    
  KJFB44                  Laparoscopic left side hemicolectomy                                       
  KJFB46                  Resection of sigmoid colon                                                 
  KJFB47                  Laparoscopic resection sigmoid colon                                       
  KJFB50                  Other resection of colon                                                   
  KJFB51                  Other laparoscopic resection of colon                                      
  KJFB60                  Resection of sigmoid colon with colostomy                                  
  KJFB61                  Laparoscopic resection of sigmoid colon colostomy and distal closure       
  KJFB63                  Other colon resection colostomy an distal closure                          
  KJFB64                  Other laparoscopic colon resection with colostomy and distal closure       
  KJFB96                  Other gut resection                                                        
  KJFB97                  Other laparoscopic gut resection                                           
  KJFH00                  Colectomy and ileorectal stoma                                             
  KJFH10                  Colectomy and ileostomy                                                    
  KJFH11                  Laparoscopic colectomy and ileostomy                                       
  KJFH20                  Proctocolectomy and ileostomy                                              
  KJFH96                  Other colectomy                                                            
  KJGB00                  Resection of rectum                                                        
  KJGB01                  Laparoscopic resection of rectum with colorectal or coloanal anastomosis   
  KJGB10                  Resection of rectum with colostomy                                         
  KJGB11                  Laparoscopic resection of rectum with colostomy                            
  KJGB30                  Abdominoperianal resection of rectum                                       
  KJGB31                  Laparoscopic and perianal excision of rectum                               
  **MRI**                                                                                            
  UXMD                    MRI of abdomen and pelvis                                                  
  UXMD10                  MRI of upper abdomen                                                       
  UXMD15                  MRI of lower abdomen, including pelvis                                     
  UXMD20                  MRI of retroperitoneum                                                     
  UXMD22                  MRI of abdominal wall                                                      
  UXMD25                  MRI of gastrointestinal tract                                              
  UXMD25A                 MRI of small bowel                                                         
  UXMD25B                 MRI of colon                                                               
  **CT scan**                                                                                        
  UXCD                    CT scan of abdomen and pelvis                                              
  UXCD00                  CT scan of abdomen                                                         
  UXCD10                  CT scan of upper abdomen                                                   
  UXCD15                  CT scan of lower abdomen, including pelvis                                 
  **Endoscopy**                                                                                      
  KUJ                     Endoscopy of gastrointestinal tract                                        
  KUJC                    Esophageal endoscopy                                                       
  KUJC02                  Esophageal endoscopy                                                       
  KUJC05                  Esophageal endoscopy with biopsy                                           
  KUJC12                  Flexible esophageal endoscopy                                              
  KUJC15                  Flexible esophageal endoscopy with biopsy                                  
  KUJF32                  Colonoscopy                                                                
  KUJF35                  Colonoscopy with biopsy                                                    
  KUJF42                  Sigmoideoscopy                                                             
  KUJF45                  Sigmoideoscopy with biopsy                                                 
  KUJF12                  Enteroscopy through stoma                                                  
  KUJF15                  Enteroscopy through stoma with biopsy                                      
  KUJF92                  Capsule enteroscopy                                                        
  KUJF82                  Double balloon endoscopy                                                   
  KUJF85                  Double balloon endoscopy with biopsy                                       
  **Chest X-ray**                                                                                    
  UXRC00                  X-ray of chest                                                             
  UXRC05                  X-ray of chest                                                             
  **Abdominal X-ray**                                                                                
  UXRD                    Abdominal X-ray                                                            
  UXRD15                  Small bowel follow-through                                                 
  UXRD20                  Small bowel follow-through with contrast in tube                           
  UXRD35                  Pouchografi                                                                
  UXZ16                   Fistulography                                                              
  ----------------------- -------------------------------------------------------------------------- ----------------------------------

**Notes:** Treatment codes used to identify eligible patients with IBD. Codes used for surgery, radiology, and endoscopic procedures.

**Abbreviations:** ATC, anatomical therapeutical chemical classification; CT, computed tomography; IBD, inflammatory bowel disease; ICD, The International Classification of Diseases; MRI, magnetic resonance imaging.
